{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:01:50Z","timestamp":1772006510572,"version":"3.50.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to thoroughly investigate the detection levels of serum Hepatitis B Virus RNA (HBV RNA) and its clinical significance in Chronic Hepatitis B (CHB) patients before and after treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Serum samples were collected from 487 chronic hepatitis B patients. First, the positivity rate and levels of serum HBV RNA were compared with other relevant indicators, and correlations were examined between untreated and treated CHB patients. Second, treated CHB patients were grouped based on their HBsAg, HBeAg, and HBV DNA status. Differences and correlations between HBV RNA and relevant indicators were further analyzed among the groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 487 patients, the positivity rate of HBV RNA was significantly higher than that of both HBV DNA and HBeAg. In the untreated group, the positivity rates of both HBV RNA and HBV DNA were significantly higher than that of HBeAg. In patients who were treated but not cured, the positivity rate of HBV RNA was significantly higher than that of both HBV DNA and HBeAg, regardless of whether patients were grouped based on HBsAg, HBeAg, or HBV DNA levels. When analyzed at specific monitoring levels, patients in the treated group showed significantly lower levels of serum HBV RNA, HBV DNA, HBeAg, HBsAg, ALT, and AST compared to those in the untreated group. Correlation analysis revealed that in untreated patients, HBV RNA was positively correlated with ALT, AST, HBsAg, HBeAg, and HBV DNA. However, in the treated group and in those with low HBsAg, HBeAg, and HBV DNA levels, the correlation between HBV RNA and other markers was weakened.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HBV RNA exhibits greater sensitivity and accuracy in reflecting the status of viruses, particularly in patients undergoing antiviral therapy. It provides unique advantages in monitoring treatment efficacy and assessing persistent viral transcriptional activity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1689229","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:05:34Z","timestamp":1772003134000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical superiority of HBV RNA testing in patients with chronic hepatitis B"],"prefix":"10.3389","volume":"17","author":[{"given":"Jing","family":"Zhou","sequence":"first","affiliation":[{"name":"Institute of Regenerative Medicine and Laboratory Technology Innovation, Qingdao University","place":["Qingdao, Shandong, China"]},{"name":"Jining Public Health Medical Center","place":["Jining, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Regenerative Medicine and Laboratory Technology Innovation, Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulin","family":"Yang","sequence":"additional","affiliation":[{"name":"Jining Public Health Medical Center","place":["Jining, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomin","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Regenerative Medicine and Laboratory Technology Innovation, Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhua","family":"Xu","sequence":"additional","affiliation":[{"name":"Institute of Regenerative Medicine and Laboratory Technology Innovation, Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn501113-20221204-00607","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)","volume":"30","year":"2022","journal-title":"Chin J Hepatol"},{"key":"B2","volume-title":"Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016\u20132021: actions for impact","year":"2021"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.12449\/JCH250201","article-title":"Establishing a public health management model to promote the elimination of viral hepatitis threats","volume":"41","author":"Wang","year":"2025","journal-title":"J Clin Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29479","article-title":"Epigenetic regulation of hepatitis B virus covalently closed circular DNA: implications for epigenetic therapy against chronic hepatitis B","volume":"66","author":"Hong","year":"2017","journal-title":"Hepatology."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112430","article-title":"New insights on molecular mechanism of hepatitis B virus covalently closed circular DNA formation","volume":"9","author":"Marchetti","year":"2020","journal-title":"Cells."},{"key":"B6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/hep.32352","article-title":"Quantified integrated hepatitis B virus is related to viral activity in patients with chronic hepatitis B","volume":"76","author":"Erken","year":"2022","journal-title":"Hepatology."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.06.037","article-title":"Hepatitis B virus DNA integration: implications for diagnostics, therapy, and outcome","volume":"81","author":"Zoulim","year":"2024","journal-title":"J Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15757","article-title":"Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: is monotherapy enough","volume":"37","author":"Liang","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.cgh.2018.10.037","article-title":"Long-term efficacy of tenofovir disoproxil fumarate monotherapy for multidrug-resistant chronic HBV infection","volume":"17","author":"Lee","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/jvh.12613","article-title":"No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg\u2013 patients with chronic hepatitis B after 8 years of treatment","volume":"24","author":"Liu","year":"2017","journal-title":"J Viral Hepat."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab596","article-title":"Earlier and higher rate of hepatitis B virus relapse after discontinuing tenofovir versus entecavir in hepatitis B e antigen\u2013positive patients","volume":"225","author":"Chen","year":"2022","journal-title":"J Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15140","article-title":"Off-tenofovir hepatitis flares in HBeAg-negative patients occur earlier, more frequent and severe than those off-entecavir therapies","volume":"42","author":"Liu","year":"2022","journal-title":"Liver Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00046-19","article-title":"Hepatitis B virus: advances in prevention, diagnosis, and therapy","volume":"33","author":"Nguyen","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02149-21","article-title":"Standardized hepatitis B virus RNA quantification in untreated and treated chronic patients: a promising marker of infection follow-up","volume":"10","author":"Cortese","year":"2022","journal-title":"Microbiol Spectr."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16538","article-title":"Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos(t)ide analogue treatment","volume":"54","author":"Xia","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jinf.2021.08.044","article-title":"On-treatment HBV RNA dynamic predicts entecavir-induced HBeAg seroconversion in children with chronic hepatitis B","volume":"83","author":"Wu","year":"2021","journal-title":"J Infect"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-020-01471-2","article-title":"Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment","volume":"18","author":"Wang","year":"2021","journal-title":"Virol J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13272","article-title":"Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B","volume":"27","author":"van Campenhout","year":"2020","journal-title":"J Viral Hepat."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i6.719","article-title":"Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients","volume":"25","author":"Luo","year":"2019","journal-title":"World J Gastroenterol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12876-019-0966-4","article-title":"Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32018","article-title":"Comparison of HBV RNA and hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in North America","volume":"74","author":"Ghany","year":"2021","journal-title":"Hepatology."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J Hepatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/cld.728","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"12","author":"Terrault","year":"2018","journal-title":"Clin Liver Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cgh.2019.07.010","article-title":"Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries","volume":"18","author":"Hou","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai","year":"2006","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/genes10040260","article-title":"Meeting the challenge of eliminating chronic hepatitis B infection","volume":"10","author":"Revill","year":"2019","journal-title":"Genes."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.08.022IF","article-title":"Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B","volume":"66","author":"Lai","year":"2017","journal-title":"J Hepatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.05.029","article-title":"Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound","volume":"65","author":"Wang","year":"2016","journal-title":"J Hepatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1689229\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:05:38Z","timestamp":1772003138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1689229\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2026.1689229"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1689229","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"article-number":"1689229"}}